• EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1

  2026-07-03

  EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1-amine hydrochloride) is a water-soluble carbodiimide reagent designed for efficient amide bond formation in peptide synthesis and bioconjugation workflows. It is not suitable for in vivo or clinical use and is best applied in controlled, in vitro laboratory protocols where high-yield coupling in aqueous environments is required.

• PKH26 Red Fluorescent Cell Linker Kit: Practical Workflow Gu

  2026-07-03

  The PKH26 Red Fluorescent Cell Linker Kit enables stable, membrane-specific fluorescent labeling for cell tracing and proliferation detection in vitro and in vivo. It should be exclusively used for labeling cell membrane lipid regions—not for intracellular or non-membrane applications. Strict adherence to membrane-labeling workflows is essential to ensure data reliability and minimize background signal.

• Dasatinib Monohydrate: Experimental Mastery in BCR-ABL Resea

  2026-07-02

  Dasatinib Monohydrate (BMS-354825) empowers precise modeling of imatinib-resistant BCR-ABL and complex tyrosine kinase signaling in leukemia and tumor microenvironments. This guide details workflow strategies, troubleshooting, and practical protocol optimizations for maximizing reproducibility and insight in translational kinase inhibition studies.

• Methyl-β-cyclodextrin: Technical Use and Protocol Parameters

  2026-07-02

  Methyl-β-cyclodextrin addresses the need for selective extraction of cholesterol and specific membrane lipids, making it essential for studies of membrane fluidity, lipid raft disruption, and cholesterol-dependent signaling pathways. It is strictly intended for controlled laboratory research and should not be used for diagnostic or medical purposes.

• Cardamomin Mitigates Oxidative Damage in Ischemic Stroke Mod

  2026-07-01

  This study elucidates the neuroprotective effects of cardamomin, a chalcone from Amomum villosum, against oxidative damage in both cellular and rodent models of cerebral ischemic stroke. Through modulation of the NRF2 signaling pathway and inhibition of cell death mechanisms, cardamomin demonstrates significant potential for translational neuroprotection research.

• Canagliflozin Remodels Kidney Mitochondria in Diabetic Hyper

  2026-07-01

  This study demonstrates that Canagliflozin, a selective SGLT2 inhibitor, enhances both the structural complexity and functional capacity of proximal tubular cell mitochondria in hypertensive–diabetic mice. The findings suggest a mechanistic basis for kidney protection that extends beyond glycemic control and highlight the mitochondrial effects as a promising target in diabetic kidney disease research.

• GSK J4 HCl: JMJD3 Inhibitor Workflows for Epigenetic Researc

  2026-06-30

  GSK J4 HCl, a potent JMJD3 inhibitor, empowers researchers to dissect histone demethylation's role in immune modulation and inflammation. This guide delivers actionable workflow enhancements, troubleshooting strategies, and experimental insights for advanced epigenetic regulation research.

• Translational Power of SB203580: Precision p38 MAPK Inhibiti

  2026-06-30

  Explore how SB 203580, a selective ATP-competitive p38 MAPK inhibitor, unlocks new vistas in inflammation, neuroprotection, and multidrug resistance reversal. This thought-leadership article bridges mechanistic insight and strategic protocols for translational researchers, contextualizing SB203580’s utility within emerging disease models—such as periodontitis-exacerbated COPD—and offering workflow guidance grounded in the latest evidence.

• HyperScribe T7 Cy3 RNA Labeling Kit: Precision for Tumor RNA

  2026-06-29

  Explore how the HyperScribe T7 High Yield Cy3 RNA Labeling Kit enables fluorescent RNA probe synthesis with unmatched control and sensitivity. This article uniquely bridges probe design with advances in targeted mRNA delivery for tumor research.

• Naloxone Hydrochloride: Advanced Protocols in Opioid Researc

  2026-06-29

  Naloxone hydrochloride is redefining opioid receptor antagonist workflows with high-purity, cross-receptor activity, and unique applications in neural and immune assays. This article delivers actionable protocols, troubleshooting strategies, and cross-domain insights for researchers seeking robust, reproducible data.

• PKM2 Inhibitor (Compound 3k): Precision in Cancer Metabolism

  2026-06-28

  PKM2 inhibitor (compound 3k) empowers researchers to dissect tumor metabolism and immune cell programming with unrivaled selectivity. Its robust efficacy against cancer cells and practical workflow flexibility make it indispensable for advanced metabolic, oncology, and immunometabolism research.

• (+)-Bicuculline: Technical Guidance for GABAA Antagonist Use

  2026-06-27

  (+)-Bicuculline is a classical GABAA receptor antagonist used to dissect inhibitory neurotransmission and modulate synaptic NMDA receptor signaling in neuroscience research. It is not suitable for diagnostic or clinical applications, and strict control of solubility and storage parameters is essential to ensure experimental reliability.

• Oligo (dT) 25 Beads: Enabling Precision mRNA Isolation in Ca

  2026-06-26

  Explore how Oligo (dT) 25 Beads revolutionize eukaryotic mRNA isolation with superparamagnetic bead technology. This article uniquely connects cutting-edge purification to translational cancer research, offering protocol insights and critical analysis for advanced molecular workflows.

• Tomivosertib Suppresses Spontaneous Activity in Human DRG Ne

  2026-06-26

  This study provides the first direct evidence that the MNK1/2 inhibitor Tomivosertib rapidly suppresses spontaneous activity in human dorsal root ganglion neurons from neuropathic pain patients. The findings highlight the MNK-eIF4E signaling pathway as a modifiable driver of neuronal hyperexcitability, opening new avenues for translational pain research.

• Liposomal Chlorin e6 PDT Triggers Pyroptosis and Tumor Immun

  2026-06-25

  The reference study demonstrates that liposomal Chlorin e6-mediated photodynamic therapy (PDT) eradicates breast cancer cells by inducing pyroptosis via mitochondrial oxidative damage and caspase-1 activation. This mechanism not only destroys tumor cells but also enhances anti-tumor immune responses, offering a promising approach for combinatorial cancer therapies.

452 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page